Peptide-Conjugated Vascular Endothelial Extracellular Vesicles Encapsulating Vinorelbine for Lung Cancer Targeted Therapeutics
<p>High expression of EGFR is correlated with poor survival of patients with lung cancer. (<b>A</b>) Bar graphs showing the expression of EGFR in different types of cancer compared to their respective controls. The red-colored cancer type depicts a significant difference between the normal and tumor groups. (<b>B</b>) Survival curve showing the time dependent probability of survival with EGFR expression in patients with lung cancer. (<b>C</b>–<b>F</b>) Graphs showing the positive correlations between (C) EGFR and MYC, (<b>D</b>) EGFR and CD44, (<b>E</b>) EGFR and MET, and (<b>F</b>) EGFR and KRAS. (<b>G</b>,<b>H</b>) Bar graphs showing the expression of EGFR in the (<b>G</b>) nonresponder (N = 269) and responder (N = 185) groups toward the treatment of anti-PD-L1 therapy and (<b>H</b>) nonresponder (N = 277) and responder (N = 166) groups toward the treatment of anti-PD-1 therapy. The difference between the nonresponders and responders was compared using Mann–Whitney test. Significance level set at * <span class="html-italic">p</span> < 0.05 and ** <span class="html-italic">p</span> < 0.01.</p> "> Figure 2
<p>Enhanced expression of EGFR on lung cancer cells under hypoxia. Immunofluorescence microscopy showing the expression and distribution pattern of EGFR protein (green color) in A549 lung cancer cells at (<b>A</b>,<b>B</b>) 20× and 40× magnifications and (<b>C</b>) the corresponding enlarged images. (<b>D</b>,<b>E</b>) Image flow cytometry-based expression of EGFR on the A549 cells under normal and hypoxic conditions (24 h incubation) and the corresponding quantitative bar graph. Comparison between the normoxia and hypoxia groups was performed using the student’s <span class="html-italic">t</span>-test with a significance level of * <span class="html-italic">p</span> < 0.01.</p> "> Figure 3
<p>Isolation and characterization of EVs from endothelial cells: (<b>A</b>) representative bright-field image of HUVECs that had been cultured in EV-depleted medium for 24 h, before the isolation of EVs. (<b>B</b>–<b>D</b>) Representative (<b>B</b>) size distribution plot of the HUVEC-EVs; (<b>C</b>,<b>D</b>) immunogold dots showing the expression of CD63 on the HUVEC-EVs. (<b>E</b>) Representative brightfield images showing the migration of A549 cells at the start and 24 h. after the addition of HUVEC-EVs at different dilutions (1× and 9× with x = 1.73 × 10<sup>9</sup> particles/mL). Scale bars = (<b>A</b>), 20 nm; (<b>C</b>,<b>D</b>), 100 nm; (<b>E</b>), 50 nm.</p> "> Figure 4
<p>Characterization of engineered EVs with GE11 peptide via postinsertion technique: (<b>A</b>) a schematic showing the functionalization of HUVEC-EVs with the postinsertion of GE11 peptide; (<b>B</b>) representative FT-IR graphs with peaks characteristic for HUVEC-EVs, GE11 peptide, and GE11-HUVEC-EVs; (<b>C</b>,<b>D</b>) zeta potential graphs and the corresponding quantitative bar graph for the EVs before and after postinsertion of the GE11 peptide. Data are shown as the mean ± S.E.M. (N = 2). The statistical analysis was performed using the Student’s <span class="html-italic">t</span>-test for the control HUVEC-EVs vs. GE11-HUVEC-EVs. Significance levels set at * <span class="html-italic">p</span> < 0.05 and ** <span class="html-italic">p</span> < 0.01; ns = not significant.</p> "> Figure 5
<p>Effect of GE11-HUVEC-EVs-Vin on malignant phenotypes of A549 lung cancer cells. (<b>A</b>–<b>D</b>) GE11-peptide-engineered endothelial cell EVs are efficiently internalized by lung cancer cells. Representative (<b>A</b>–<b>C</b>) immunofluorescence images and (<b>D</b>) a violin plot showing the uptake of (<b>A</b>) PBS, (<b>B</b>) HUVEC-EVs, and (<b>C</b>) GE11-HUVEC-EVs by the A549 cells (scale bar = 100 nm). (<b>E</b>) GE11-HUVEC-EVs-Vin significantly reduced the cell viability of A549 cells. Representative bar graph showing the effect of the following different treatment groups—HUVEC-EVs, GE11-HUVEC-EVs, vinorelbine (Vin), HUVEC-EVs-Vin, and GE11-HUVEC-EVs-Vino—on the proliferation of A549 cells, as detected by the MTT cell viability assay. (<b>F</b>,<b>G</b>) Representative immunofluorescence images showing the expression of Annexin-V in A549 cells treated with Vin or HUVEC-EVs-Vin (scale bar = 100 nm). (<b>H</b>,<b>I</b>) GE11-HUVEC-EVs significantly reduced the migration of A549 cells under hypoxia. (<b>H</b>) Representative images from the Transwell chamber (scale bar = 100 nm) and (<b>I</b>) a bar graph showing the effects of the following different treatment groups—HUVEC-EVs, GE11-HUVEC-EVs, Vinorelbine, HUVEC-EVs-Vin, and GE11-HUVEC-EVs-Vino—on the migration ability of A549 cells, as detected by the Transwell migration assay under hypoxia, compared to the vehicle-treated and untreated normoxia. Data are shown as the means ± standard error means (S.E.M.), with N = 3 replicates per group. Significance levels set at * <span class="html-italic">p</span> < 0.05 and ** <span class="html-italic">p</span> < 0.01; ns = not significant. Statistical comparisons were performed for the control vs. HUVEC-EVs; control vs. GE11-HUVEC-EVs; control vs. vinorelbine; control vs. HUVEC-EVs-Vin; and control vs. GE11-HUVEC-EVs-Vin with one-way ANOVA. For comparison of the HUVEC-EVs or GE11-HUVEC-EVs or vinorelbine or HUVEC-EVs-Vin with GE11-HUVEC-EVs-Vin, the Student’s <span class="html-italic">t</span>-test was applied.</p> "> Figure 6
<p>GE11-HUVEC-EVs-Vin significantly reduced the expression of EGFR and Ki67 in the tumor tissue of a mouse model of lung cancer: (<b>A</b>,<b>B</b>) representative H&E staining of the lung tissue of SCID WT and lung-cancer-cell-based tumor mouse model (scale bar = 50 µm); (<b>C</b>–<b>G</b>) representative immunofluorescence images showing the effects of different treatments—HUVEC-EVs, GE11-HUVEC-EVs, vinorelbine (Vin), HUVEC-EVs-Vin, and GE11-HUVEC-EVs-Vin—on nuclei (depicted by blue color; DAPI), EGFR (green), and Ki67 (red) in a lung cancer cell-based tumor mouse model (scale bar = 50 µm).</p> ">
Abstract
:1. Introduction
2. Materials and Methods
2.1. Ethics Statement
2.2. Analysis of Single-Cell and Bulk RNA-Seq Data
2.3. In Silico Analysis for Target Identification
2.4. Molecular Docking
2.5. Cell Culture
2.6. Isolation of HUVEC-EVs and GE11-HUVEC-EVs
2.7. Surface Engineering of HUVECs to Express GE11 Peptide (GE11-HUVEC-EVs)
2.8. Analysis of the Sizes and Concentration of EVs via Nano Tracking Analyzer
2.9. Transmission Electron Microscopy (TEM)
2.10. Immunogold EM Analysis
2.11. Imaging Flow Cytometry Analysis of EVs
2.12. Fourier-Transform Infrared (FT-IR) Microscopy
2.13. Loading of Vinorelbine on HUVEC-EVs and GE11-HUVEC-EVs and Their Evaluation
2.14. Labeling of EVs
2.15. EV Uptake Assay
2.16. Cell Viability Assay
2.17. Migration Assay
2.18. Apoptosis Assay
2.19. Immunocytochemistry
2.20. Development of Cancer Mouse Model
2.21. Hematoxylin–Eosin (H&E) Staining
2.22. Immunohistochemistry
2.23. Statistical Analysis
3. Results
3.1. EGFR Gene Overexpression Is Associated with Poor Survival of Patients with Lung Cancer
3.2. EGFR Protein Is Significantly Overexpressed in the A549 Cells in Hypoxic TMEs
3.3. Endothelial-Cell-Derived EVs Attenuate the Migration of Lung Cancer Cells
3.4. Engineering Endothelial Cells EVs via GE11 Peptide Postinsertion and Loading of Vinorelbine
3.5. GE11-Peptide-Engineered EVs Were Incorporated into EGFR-Expressing Lung Cancer Cells and Showed Tumoricidal Effects In Vitro
3.6. GE11-HUVEC-EVs-Vin Showed a Tumoricidal Effect in an In Vivo Lung-Cancer-Cell-Based Tumor Mouse Model
4. Discussion
Supplementary Materials
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- Baudendistel, I.; Winkler, E.; Kamradt, M.; Brophy, S.; Längst, G.; Eckrich, F.; Heinze, O.; Bergh, B.; Szecsenyi, J.; Ose, D. Cross-sectoral cancer care: Views from patients and health care professionals regarding a personal electronic health record. Eur. J. Cancer Care 2017, 26, e12429. [Google Scholar] [CrossRef]
- Azami-Aghdash, S.; Ghojazadeh, M.; Sheyklo, S.G.; Daemi, A.; Kolahdouzan, K.; Mohseni, M.; Moosavi, A. Breast Cancer Screening Barriers from the Womans Perspective: A Meta-synthesis. Asian Pac. J. Cancer Prev. 2015, 16, 3463–3471. [Google Scholar] [CrossRef]
- Murphy, K.M.; Nguyen, V.; Shin, K.; Sebastian-Deutsch, A.; Frieden, L. Health Care Professionals and the Employment-Related Needs of Cancer Survivors. J. Occup. Rehabil. 2017, 27, 296–305. [Google Scholar] [CrossRef]
- Maleki, D.; Ghojazadeh, M.; Mahmoudi, S.-S.; Mahmoudi, S.-M.; Pournaghi-Azar, F.; Torab, A.; Piri, R.; Azami-Aghdash, S.; Naghavi-Behzad, M. Epidemiology of Oral Cancer in Iran: A Systematic Review. Asian Pac. J. Cancer Prev. 2015, 16, 5427–5432. [Google Scholar] [CrossRef]
- Naghavi, M.; Abajobir, A.A.; Abbafati, C.; Abbas, K.M.; Abd-Allah, F.; Abera, S.F.; Aboyans, V.; Adetokunboh, O.; Afshin, A.; Agrawal, A.; et al. Global, regional, and national age-sex specific mortality for 264 causes of death, 1980–2016: A systematic analysis for the Global Burden of Disease Study 2016. Lancet 2017, 390, 1151–1210. [Google Scholar] [CrossRef]
- Ferraz, A.F.B.; Rosim, R.; Anaya, P. Standardization Process of Raw Datasus and Consumption Analysis Of Oncology Therapies In The Brazil Public Health Care System: A Comparison Between Raw And Standardized Dataset In Colorectal And Lung Cancer. Value Health 2015, 18, A811. [Google Scholar] [CrossRef]
- Faris, N.; Yu, X.; Sareen, S.; Signore, R.S.; McHugh, L.M.; Roark, K.; Robbins, E.T.; Osarogiagbon, R.U. Preoperative Evaluation of Lung Cancer in a Community Health Care Setting. Ann. Thorac. Surg. 2015, 100, 394–400. [Google Scholar] [CrossRef]
- Ryoo, J.J.; Ordin, D.L.; Antonio, A.L.M.; Oishi, S.M.; Gould, M.K.; Asch, S.M.; Malin, J.L. Patient Preference and Contraindications in Measuring Quality of Care: What Do Administrative Data Miss? J. Clin. Oncol. 2013, 31, 2716–2723. [Google Scholar] [CrossRef]
- Sundaram, B.; Kazerooni, E.A. Preface. Radiol. Clin. N. Am. 2012, 50, xi. [Google Scholar] [CrossRef]
- Zappa, C.; Mousa, S.A. Non-small cell lung cancer: Current treatment and future advances. Transl. Lung Cancer Res. 2016, 5, 288–300. [Google Scholar] [CrossRef]
- Oser, M.G.; Niederst, M.J.; Sequist, L.V.; Engelman, J.A. Transformation from non-small-cell lung cancer to small-cell lung cancer: Molecular drivers and cells of origin. Lancet Oncol. 2015, 16, e165–e172. [Google Scholar] [CrossRef]
- Lemjabbar-Alaoui, H.; Hassan, O.U.; Yang, Y.-W.; Buchanan, P. Lung cancer: Biology and treatment options. Biochim. Biophys. Acta Rev. Cancer 2015, 1856, 189–210. [Google Scholar] [CrossRef]
- Halezeroğlu, S.; Semih, H. Advantages and disadvantages of single incision VATS in major anatomical resection for lung cancer. J. Vis. Surg. 2017, 3, 115. [Google Scholar] [CrossRef]
- Juretic, A.; Frobe, A.; Brozic, J.M.; Bilic, L.G.; Basic-Koretic, M. YI02.03 Dose Limitations for Radiotherapy of Lung Cancer. J. Thorac. Oncol. 2017, 12, S229–S231. [Google Scholar] [CrossRef]
- Chidambaram, M.; Manavalan, R.; Kathiresan, K. Nanotherapeutics to Overcome Conventional Cancer Chemotherapy Limitations. J. Pharm. Pharm. Sci. 2011, 14, 67–77. [Google Scholar] [CrossRef]
- Allen, T.M.; Cullis, P.R. Drug Delivery Systems: Entering the Mainstream. Science 2004, 303, 1818–1822. [Google Scholar] [CrossRef]
- Hussain, S.; Pluckthun, A.; Allen, T.M.; Zangemeister-Wittke, U. Antitumor activity of an epithelial cell adhesion molecule–targeted nanovesicular drug delivery system. Mol. Cancer Ther. 2007, 6, 3019–3027. [Google Scholar] [CrossRef]
- Torchilin, V.P. Recent advances with liposomes as pharmaceutical carriers. Nat. Rev. Drug Discov. 2005, 4, 145–160. [Google Scholar] [CrossRef]
- Landesman-Milo, D.; Peer, D. Altering the immune response with lipid-based nanoparticles. J. Control. Release 2012, 161, 600–608. [Google Scholar] [CrossRef]
- Landesman-Milo, D.; Ramishetti, S.; Peer, D. Nanomedicine as an emerging platform for metastatic lung cancer therapy. Cancer Metastasis Rev. 2015, 34, 291–301. [Google Scholar] [CrossRef]
- György, B.; Szabó, T.G.; Pásztói, M.; Pál, Z.; Misják, P.; Aradi, B.; László, V.; Pállinger, É.; Pap, E.; Kittel, Á.; et al. Membrane vesicles, current state-of-the-art: Emerging role of extracellular vesicles. Cell. Mol. Life Sci. 2011, 68, 2667–2688. [Google Scholar] [CrossRef]
- Battistelli, M.; Falcieri, E. Apoptotic Bodies: Particular Extracellular Vesicles Involved in Intercellular Communication. Biology 2020, 9, 21. [Google Scholar] [CrossRef]
- Li, Z.; Tan, S.; Li, S.; Shen, Q.; Wang, K. Cancer drug delivery in the nano era: An overview and perspectives. Oncol. Rep. 2017, 38, 611–624. [Google Scholar] [CrossRef]
- Gu, Y.; Li, S.; Feng, S.; Ding, L.; Liu, Y.; Zhu, Q.; Qian, Z. Nanomedicine engulfed by macrophages for targeted tumor therapy. Int. J. Nanomed. 2016, 11, 4107–4124. [Google Scholar] [CrossRef]
- Kowal, J.; Tkach, M.; Théry, C. Biogenesis and secretion of exosomes. Curr. Opin. Cell Biol. 2014, 29, 116–125. [Google Scholar] [CrossRef]
- Barile, L.; Vassalli, G. Exosomes: Therapy delivery tools and biomarkers of diseases. Pharmacol. Ther. 2017, 174, 63–78. [Google Scholar] [CrossRef]
- Farooqi, A.A.; Desai, N.N.; Qureshi, M.Z.; Librelotto, D.R.N.; Gasparri, M.L.; Bishayee, A.; Nabavi, S.M.; Curti, V.; Daglia, M. Exosome biogenesis, bioactivities and functions as new delivery systems of natural compounds. Biotechnol. Adv. 2018, 36, 328–334. [Google Scholar] [CrossRef]
- Colombo, M.; Raposo, G.; Théry, C. Biogenesis, secretion, and intercellular interactions of exosomes and other extracellular vesicles. Annu. Rev. Cell Dev. Biol. 2014, 30, 255–289. [Google Scholar] [CrossRef]
- Kakarla, R.; Hur, J.; Kim, Y.J.; Kim, J.; Chwae, Y.-J. Apoptotic cell-derived exosomes: Messages from dying cells. Exp. Mol. Med. 2020, 52, 1–6. [Google Scholar] [CrossRef]
- Willms, E.; Cabañas, C.; Mäger, I.; Wood, M.J.A.; Vader, P. Extracellular Vesicle Heterogeneity: Subpopulations, Isolation Techniques, and Diverse Functions in Cancer Progression. Front. Immunol. 2018, 9, 738. [Google Scholar] [CrossRef]
- Théry, C.; Zitvogel, L.; Amigorena, S. Exosomes: Composition, biogenesis and function. Nat. Rev. Immunol. 2002, 2, 569–579. [Google Scholar] [CrossRef]
- Kahlert, C.; Melo, S.; Protopopov, A.; Tang, J.; Seth, S.; Koch, M.; Zhang, J.; Weitz, J.; Chin, L.; Futreal, A.; et al. Identification of Double-stranded Genomic DNA Spanning All Chromosomes with Mutated KRAS and p53 DNA in the Serum Exosomes of Patients with Pancreatic Cancer. J. Biol. Chem. 2014, 289, 3869–3875. [Google Scholar] [CrossRef]
- Vlassov, A.V.; Magdaleno, S.; Setterquist, R.; Conrad, R. Exosomes: Current knowledge of their composition, biological functions, and diagnostic and therapeutic potentials. Biochim. Biophys. Acta -Gen. Subj. 2012, 1820, 940–948. [Google Scholar] [CrossRef]
- Tkach, M.; Théry, C. Communication by Extracellular Vesicles: Where We Are and Where We Need to Go. Cell 2016, 164, 1226–1232. [Google Scholar] [CrossRef]
- Schiffelers, R.; Kooijmans, S.; Vader, P.; Dommelen, V.; Solinge, V. Exosome mimetics: A novel class of drug delivery systems. Int. J. Nanomed. 2012, 7, 1525. [Google Scholar] [CrossRef]
- Van Dommelen, S.M.; Vader, P.; Lakhal, S.; Kooijmans, S.; van Solinge, W.W.; Wood, M.J.; Schiffelers, R.M. Microvesicles and exosomes: Opportunities for cell-derived membrane vesicles in drug delivery. J. Control. Release 2012, 161, 635–644. [Google Scholar] [CrossRef]
- Ohno, S.-I.; Takanashi, M.; Sudo, K.; Ueda, S.; Ishikawa, A.; Matsuyama, N.; Fujita, K.; Mizutani, T.; Ohgi, T.; Ochiya, T.; et al. Systemically Injected Exosomes Targeted to EGFR Deliver Antitumor MicroRNA to Breast Cancer Cells. Mol. Ther. 2013, 21, 185–191. [Google Scholar] [CrossRef]
- Rani, S.; Ryan, A.E.; Griffin, M.D.; Ritter, T. Mesenchymal Stem Cell-derived Extracellular Vesicles: Toward Cell-free Therapeutic Applications. Mol. Ther. 2015, 23, 812–823. [Google Scholar] [CrossRef]
- György, B.; Sage, C.; Indzhykulian, A.A.; Scheffer, D.I.; Brisson, A.R.; Tan, S.; Wu, X.; Volak, A.; Mu, D.; Tamvakologos, P.I.; et al. Rescue of Hearing by Gene Delivery to Inner-Ear Hair Cells Using Exosome-Associated AAV. Mol. Ther. 2017, 25, 379–391. [Google Scholar] [CrossRef]
- Kamerkar, S.; LeBleu, V.S.; Sugimoto, H.; Yang, S.; Ruivo, C.F.; Melo, S.A.; Lee, J.J.; Kalluri, R. Exosomes facilitate therapeutic targeting of oncogenic KRAS in pancreatic cancer. Nature 2017, 546, 498–503. [Google Scholar] [CrossRef]
- Robbins, P.D.; Dorronsoro, A.; Booker, C.N. Regulation of chronic inflammatory and immune processes by extracellular vesicles. J. Clin. Investig. 2016, 126, 1173–1180. [Google Scholar] [CrossRef]
- Tao, K.; Liu, J.; Liang, J.; Xu, X.; Xu, L.; Mao, W. Vascular endothelial cell-derived exosomal miR-30a-5p inhibits lung adenocarcinoma malignant progression by targeting CCNE2. Carcinogenesis 2021, 42, 1056–1067. [Google Scholar] [CrossRef]
- Liu, H.; Zhao, J.; Yang, Y.; Jin, G.; Zhang, X.; Wang, D.; Xie, C.; Liu, K.; Chen, X.; Li, X.; et al. Human umbilical vein endothelial cell vaccine suppresses the angiogenesis of esophageal squamous cell carcinoma in a humanized mouse model. Oncol. Rep. 2018, 40, 3006–3014. [Google Scholar] [CrossRef]
- Zhang, Q.; Xie, C.; Wang, D.; Yang, Y.; Liu, H.; Liu, K.; Zhao, J.; Chen, X.; Zhang, X.; Yang, W.; et al. Improved Antitumor Efficacy of Combined Vaccine Based on the Induced HUVECs and DC-CT26 Against Colorectal Carcinoma. Cells 2019, 8, 494. [Google Scholar] [CrossRef]
- Scagliotti, G.V.; Selvaggi, G.; Novello, S.; Hirsch, F.R. The Biology of Epidermal Growth Factor Receptor in Lung Cancer. Clin. Cancer Res. 2004, 10, 4227S–4232S. [Google Scholar] [CrossRef]
- Genta, I.; Chiesa, E.; Colzani, B.; Modena, T.; Conti, B.; Dorati, R. GE11 Peptide as an Active Targeting Agent in Antitumor Therapy: A Minireview. Pharmaceutics 2017, 10, 2. [Google Scholar] [CrossRef]
- Kang, D.H.; Kim, J.O.; Jung, S.S.; Park, H.S.; Chung, C.; Park, D.; Lee, J.E. Efficacy of Vinorelbine Monotherapy as Third- or Further-Line Therapy in Patients with Advanced Non-Small-Cell Lung Cancer. Oncology 2019, 97, 356–364. [Google Scholar] [CrossRef]
- Kang, D.H.; Park, D.I.; Chung, C.; Moon, J.Y.; Park, H.S.; Jung, S.S.; Kim, J.O.; Lee, J.E. Efficacy of weekly vinorelbine monotherapy in patients with lung adenocarcinoma. J. Clin. Oncol. 2018, 36, e21157. [Google Scholar] [CrossRef]
- Elderly Lung Cancer Vinorelbine Italian Study Group. Effects of Vinorelbine on Quality of Life and Survival of Elderly Patients with Advanced Non-Small-Cell Lung Cancer. JNCI J. Natl. Cancer Inst. 1999, 91, 66–72. [Google Scholar] [CrossRef]
- Chavda, V.P.; Patel, A.B.; Mistry, K.J.; Suthar, S.F.; Wu, Z.-X.; Chen, Z.-S.; Hou, K. Nano-Drug Delivery Systems Entrapping Natural Bioactive Compounds for Cancer: Recent Progress and Future Challenges. Front. Oncol. 2022, 12, 867655. [Google Scholar] [CrossRef]
- Callaghan, R.; Luk, F.; Bebawy, M. Inhibition of the Multidrug Resistance P-Glycoprotein: Time for a Change of Strategy? Drug Metab. Dispos. 2014, 42, 623–631. [Google Scholar] [CrossRef]
- Uribe, M.L.; Marrocco, I.; Yarden, Y. EGFR in Cancer: Signaling Mechanisms, Drugs, and Acquired Resistance. Cancers 2021, 13, 2748. [Google Scholar] [CrossRef]
- Zilionis, R.; Engblom, C.; Pfirschke, C.; Savova, V.; Zemmour, D.; Saatcioglu, H.D.; Krishnan, I.; Maroni, G.; Meyerovitz, C.V.; Kerwin, C.M.; et al. Single-Cell Transcriptomics of Human and Mouse Lung Cancers Reveals Conserved Myeloid Populations across Individuals and Species. Immunity 2019, 50, 1317–1334.e10. [Google Scholar] [CrossRef]
- Little, C.D.; Nau, M.M.; Carney, D.N.; Gazdar, A.F.; Minna, J.D. Amplification and expression of the c-myc oncogene in human lung cancer cell lines. Nature 1983, 306, 194–196. [Google Scholar] [CrossRef]
- Thakur, A.; Xu, C.; Li, W.K.; Qiu, G.; He, B.; Ng, S.-P.; Wu, C.-M.L.; Lee, Y. In vivo liquid biopsy for glioblastoma malignancy by the AFM and LSPR based sensing of exosomal CD44 and CD133 in a mouse model. Biosens. Bioelectron. 2021, 191, 113476. [Google Scholar] [CrossRef]
- Matsumoto, K.; Umitsu, M.; De Silva, D.M.; Roy, A.; Bottaro, D.P. Hepatocyte growth factor/MET in cancer progression and biomarker discovery. Cancer Sci. 2017, 108, 296–307. [Google Scholar] [CrossRef]
- Yu, J.; Wang, X.; Teng, F.; Kong, L. PD-L1 expression in human cancers and its association with clinical outcomes. OncoTargets Ther. 2016, 9, 5023–5039. [Google Scholar] [CrossRef]
- Park, Y.; Abihssira-García, I.S.; Thalmann, S.; Wiegertjes, G.F.; Barreda, D.R.; Olsvik, P.A.; Kiron, V. Imaging Flow Cytometry Protocols for Examining Phagocytosis of Microplastics and Bioparticles by Immune Cells of Aquatic Animals. Front. Immunol. 2020, 11, 203. [Google Scholar] [CrossRef]
- Dermani, F.K.; Samadi, P.; Rahmani, G.; Kohlan, A.K.; Najafi, R. PD-1/PD-L1 immune checkpoint: Potential target for cancer therapy. J. Cell. Physiol. 2019, 234, 1313–1325. [Google Scholar] [CrossRef]
- Seshacharyulu, P.; Ponnusamy, M.P.; Haridas, D.; Jain, M.; Ganti, A.K.; Batra, S.K. Targeting the EGFR signaling pathway in cancer therapy. Expert Opin. Ther. Targets 2012, 16, 15–31. [Google Scholar] [CrossRef]
- Li, Y.; Zhao, L.; Li, X.-F. Hypoxia and the Tumor Microenvironment. Technol. Cancer Res. Treat. 2021, 20, 153303382110363. [Google Scholar] [CrossRef]
- Chen, H.; Shien, K.; Suzawa, K.; Tsukuda, K.; Tomida, S.; Sato, H.; Torigoe, H.; Watanabe, M.; Namba, K.; Yamamoto, H.; et al. Elacridar, a third-generation ABCB1 inhibitor, overcomes resistance to docetaxel in non-small cell lung cancer. Oncol. Lett. 2017, 14, 4349–4354. [Google Scholar] [CrossRef]
- Riaz, M.K.; Zhang, X.; Wong, K.H.; Chen, H.; Liu, Q.; Chen, X.; Zhang, G.; Lu, A.; Yang, Z. Pulmonary delivery of transferrin receptors targeting peptide surface-functionalized liposomes augments the chemotherapeutic effect of quercetin in lung cancer therapy. Int. J. Nanomed. 2019, 14, 2879–2902. [Google Scholar] [CrossRef]
- Thakur, A.; Sidu, R.K.; Zou, H.; Alam, K.; Yang, M.; Lee, Y. Inhibition of Glioma Cells’ Proliferation by Doxorubicin-Loaded Exosomes via Microfluidics. Int. J. Nanomed. 2020, 15, 8331–8343. [Google Scholar] [CrossRef]
- Hu, Q.; Su, H.; Li, J.; Lyon, C.; Tang, W.; Wan, M.; Hu, T.Y. Clinical applications of exosome membrane proteins. Precis. Clin. Med. 2020, 3, 54–66. [Google Scholar] [CrossRef]
- Thakur, A.; Johnson, A.; Jacobs, E.; Zhang, K.; Chen, J.; Wei, Z.; Lian, Q.; Chen, H.J. Energy Sources for Exosome Communication in a Cancer Microenvironment. Cancers 2022, 14, 1698. [Google Scholar] [CrossRef]
- Gaurav, I.; Thakur, A.; Iyaswamy, A.; Wang, X.; Chen, X.; Yang, Z. Factors Affecting Extracellular Vesicles Based Drug Delivery Systems. Molecules 2021, 26, 1544. [Google Scholar] [CrossRef]
- Thakur, A.; Ke, X.; Chen, Y.-W.; Motallebnejad, P.; Zhang, K.; Lian, Q.; Chen, H.J. The mini player with diverse functions: Extracellular vesicles in cell biology, disease, and therapeutics. Protein Cell 2021, 13, 631–654. [Google Scholar] [CrossRef]
- Gaurav, I.; Wang, X.; Thakur, A.; Iyaswamy, A.; Thakur, S.; Chen, X.; Kumar, G.; Li, M.; Yang, Z. Peptide-Conjugated Nano Delivery Systems for Therapy and Diagnosis of Cancer. Pharmaceutics 2021, 13, 1433. [Google Scholar] [CrossRef]
- De Jong, O.G.; Kooijmans, S.A.A.; Murphy, D.E.; Jiang, L.; Evers, M.J.W.; Sluijter, J.P.G.; Vader, P.; Schiffelers, R.M. Drug Delivery with Extracellular Vesicles: From Imagination to Innovation. Acc. Chem. Res. 2019, 52, 1761–1770. [Google Scholar] [CrossRef]
- Jang, H.; Kim, H.; Kim, E.H.; Han, G.; Jang, Y.; Kim, Y.; Lee, J.W.; Shin, S.C.; Kim, E.E.; Kim, S.H.; et al. Post-insertion technique to introduce targeting moieties in milk exosomes for targeted drug delivery. Biomater. Res. 2023, 27, 124. [Google Scholar] [CrossRef]
- Thakur, A.; Parra, D.C.; Motallebnejad, P.; Brocchi, M.; Chen, H.J. Exosomes: Small vesicles with big roles in cancer, vaccine development, and therapeutics. Bioact. Mater. 2022, 10, 281–294. [Google Scholar] [CrossRef]
- Lorusso, G.; Rüegg, C. The tumor microenvironment and its contribution to tumor evolution toward metastasis. Histochem. 2008, 130, 1091–1103. [Google Scholar] [CrossRef]
- Raguraman, R.; Bhavsar, D.; Kim, D.; Ren, X.; Sikavitsas, V.; Munshi, A.; Ramesh, R. Tumor-targeted exosomes for delivery of anticancer drugs. Cancer Lett. 2023, 558, 216093. [Google Scholar] [CrossRef]
- Zheng, H.; Zhan, Y.; Liu, S.; Lu, J.; Luo, J.; Feng, J.; Fan, S. The roles of tumor-derived exosomes in non-small cell lung cancer and their clinical implications. J. Exp. Clin. Cancer Res. 2018, 37, 226. [Google Scholar] [CrossRef]
- Hung, M.E.; Leonard, J.N. Stabilization of Exosome-targeting Peptides via Engineered Glycosylation. J. Biol. Chem. 2015, 290, 8166–8172. [Google Scholar] [CrossRef]
- Bartha, Á.; Győrffy, B. TNMplot.com: A Web Tool for the Comparison of Gene Expression in Normal, Tumor and Metastatic Tissues. Int. J. Mol. Sci. 2021, 22, 2622. [Google Scholar] [CrossRef]
- Győrffy, B. Discovery and ranking of the most robust prognostic biomarkers in serous ovarian cancer. GeroScience 2023, 45, 1889–1898. [Google Scholar] [CrossRef]
- Thakur, A.; Qiu, G.; Xu, C.; Han, X.; Yang, T.; Ng, S.P.; Chan, K.W.Y.; Wu, C.M.L.; Lee, Y. Label-free sensing of exosomal MCT1 and CD147 for tracking metabolic reprogramming and malignant progression in glioma. Sci. Adv. 2020, 6, eaaz6119. [Google Scholar] [CrossRef]
- Kooijmans, S.A.A.; Fliervoet, L.A.L.; van der Meel, R.; Fens, M.H.A.M.; Heijnen, H.F.G.; van Bergen En Henegouwen, P.M.P.; Vader, P.; Schiffelers, R.M. PEGylated and targeted extracellular vesicles display enhanced cell specificity and circulation time. J. Control. Release 2016, 224, 77–85. [Google Scholar] [CrossRef]
- Zhu, Q.; Ling, X.; Yang, Y.; Zhang, J.; Li, Q.; Niu, X.; Hu, G.; Chen, B.; Li, H.; Wang, Y.; et al. Embryonic Stem Cells-Derived Exosomes Endowed with Targeting Properties as Chemotherapeutics Delivery Vehicles for Glioblastoma Therapy. Adv. Sci. 2019, 6, 1801899. [Google Scholar] [CrossRef]
- Hood, J.L. Post Isolation Modification of Exosomes for Nanomedicine Applications. Nanomedicine 2016, 11, 1745–1756. [Google Scholar] [CrossRef]
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Gaurav, I.; Thakur, A.; Zhang, K.; Thakur, S.; Hu, X.; Xu, Z.; Kumar, G.; Jaganathan, R.; Iyaswamy, A.; Li, M.; et al. Peptide-Conjugated Vascular Endothelial Extracellular Vesicles Encapsulating Vinorelbine for Lung Cancer Targeted Therapeutics. Nanomaterials 2024, 14, 1669. https://doi.org/10.3390/nano14201669
Gaurav I, Thakur A, Zhang K, Thakur S, Hu X, Xu Z, Kumar G, Jaganathan R, Iyaswamy A, Li M, et al. Peptide-Conjugated Vascular Endothelial Extracellular Vesicles Encapsulating Vinorelbine for Lung Cancer Targeted Therapeutics. Nanomaterials. 2024; 14(20):1669. https://doi.org/10.3390/nano14201669
Chicago/Turabian StyleGaurav, Isha, Abhimanyu Thakur, Kui Zhang, Sudha Thakur, Xin Hu, Zhijie Xu, Gaurav Kumar, Ravindran Jaganathan, Ashok Iyaswamy, Min Li, and et al. 2024. "Peptide-Conjugated Vascular Endothelial Extracellular Vesicles Encapsulating Vinorelbine for Lung Cancer Targeted Therapeutics" Nanomaterials 14, no. 20: 1669. https://doi.org/10.3390/nano14201669